Atopic Dermatitis (AD) Clinical Trial
Official title:
A Prospective, Multi-center, Post-marketing, Observational Study to Evaluate the Safety and Effectiveness of Upadacitinib in Chinese Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. This study will assess how safe and effective upadacitinib is in treating AD in adolescent and adult Chinese participants. Upadacitinib is an approved drug for treating AD. Approximately 200 adolescent and adult participants who are prescribed upadacitinib by their physician in accordance with local label will be enrolled in China. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed up for approximately 24 months per participant and 30 days after last treatment dose for safety data collection. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03151148 -
Targeted Microbiome Transplant in Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05456529 -
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT04056130 -
A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04173442 -
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
|
||
| Completed |
NCT05372653 -
A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT03168113 -
Atopic Dermatitis (AD) and Food Allergy
|
N/A | |
| Terminated |
NCT03389893 -
Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis
|
Phase 4 | |
| Recruiting |
NCT04541810 -
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
|
||
| Completed |
NCT02357940 -
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
|
N/A | |
| Recruiting |
NCT05667623 -
To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD
|
Phase 3 | |
| Recruiting |
NCT05650320 -
To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD
|
Phase 3 | |
| Completed |
NCT01979016 -
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
|
Phase 2 | |
| Withdrawn |
NCT04666675 -
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
|
Phase 3 | |
| No longer available |
NCT04159597 -
Expanded Access to Upadacitinib
|